Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Target ID: TTDC00198

Target Information
NameHCV polymerase    
Type of targetClinical trial target    
DiseaseHepatitis C
[ICD9: 070.4, 070.5, 070.70   ICD10: B17.1, B18.2]
[1]
Drug(s)BI 207127Phase IIHepatitis C[2]
BMS 791325Phase IIHepatitis C[3]
FilibuvirPhase IIHepatitis C[4]
PSI-7977Phase IIHepatitis C[5]
R7128Phase IIHepatitis C[6]
RG7128Phase IIHepatitis C[5]
SetrobuvirPhase IIHepatitis C[7]
TegobuvirPhase IIHepatitis C[8]
VX-222Phase IIHepatitis C[9]
VX-759Phase IIHepatitis C[9]
ABT-072Phase IHepatitis C[10]
ABT-333Phase IHepatitis C[10]
IDX-189Phase IHepatitis C[11]
MK-3281Phase IHepatitis C[12]
PSI-938Phase IHepatitis C[5]
TMC649128Phase IHepatitis C[13]
VX-916Phase IHepatitis C[9]
HCV-796Halted in Phase IIHepatitis C[14]
XTL-2125Withdrawn in Phase IHepatitis C[14]
IDX375PreclinicalHepatitis C[15][16]
BioChemical ClassRNA-directed RNA polymerase    
EC NumberEC 3.4.22.-
UniProt IDQ68929
SequenceCGNTITCYLKASAACRAAKLQDCTMLVCGDDLVVICESAGTQEDAASLRVFTEAMTRYSA PPGDPPQPEYDLELITSCSSNVSVAHDASGK
Related US Patent6,528,252
Target ValidationClick to Find Target Validation Information.    
InhibitorABT-072[10]
ABT-333[10]
BI 207127[2]
BMS 791325[3]
Filibuvir[4]
HCV-796[14]
IDX-189[11]
IDX375[15][16]
MK-3281[12]
PSI-7977[5]
PSI-938[5]
R7128[6]
RG7128[5]
Setrobuvir[7]
TMC649128[13]
Tegobuvir[8]
VX-222[9]
VX-759[9]
VX-916[9]
XTL-2125[14]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Recent advances in prevention and treatment of hepatitis C virus infections. Prog Drug Res. 2001;Spec No:79-110. To Reference
Ref 22011 Pipeline of Boehringer Ingelheim Pharma. To Reference
Ref 32011 Pipeline of Bristol-Myers Squibb. To Reference
Ref 42011 Pipeline of Pfizer. To Reference
Ref 52011 Pipeline of Pharmasset. To Reference
Ref 6Roche. Product Development Pipeline. July 29 2009. To Reference
Ref 72011 Pipeline of Anadys Pharmaceuticals. To Reference
Ref 82011 Pipeline of Gilead. To Reference
Ref 92011 Pipeline of Vertex. To Reference
Ref 102011 Pipeline of Abbott. To Reference
Ref 112011 Pipeline of Idenix. To Reference
Ref 122011 Pipeline of Merck. To Reference
Ref 132011 Pipeline of Medivir. To Reference
Ref 14Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19. To Reference
Ref 15Idenix. Product Development Pipeline. February 2009. To Reference
Ref 16Idenix. News for Idenix. 2009. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543